Calmare Therapeutics Incorporated
CTTC
Other OTC0.00
USD
- -
- -
Return %
Stock
S&P500
1Y
-95.00
26.53
3Y
-90.00
76.60
5Y
-90.00
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Conrad F. Mir
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- IPO Date
- Nov 22, 2022
- Similar Companies
- Business
- Calmare Therapeutics Incorporated (OTCQB: CTTC) develops and commercializes proprietary medical devices for chronic neuropathic pain mitigation and wound care; its flagship product, the Calmare Pain Therapy Device, delivers non-pharmacological, non-addictive, non-invasive scrambler therapy via surface electrodes to treat severe, drug-resistant pain conditions including chemotherapy-induced peripheral neuropathy and oncologic pain; the company supplements devices with private-label neurostimulation and sensory electrodes. The Calmare device holds U.S. FDA 510(k) clearance (K081255), European CE mark, and serves as a preferred U.S. federal government vendor under GSA contract V797P-4300b since 2010, enabling sales to military hospitals. Founded in 1968 and headquartered in Fairfield, Connecticut, Calmare Therapeutics operates globally, with commercial distribution in the United States, Europe, and other regions under respective health ministry approvals.
Financial Analysis: Competitive Technologies (OTCMKTS:CTTC) vs. Envoy Medical (NASDAQ:COCH)